Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Natco Pharma plans to...

    Natco Pharma plans to launch 8-10 branded formulations this year

    Written by Ruby Khatun Khatun Published On 2017-06-05T15:21:32+05:30  |  Updated On 5 Jun 2017 3:21 PM IST

    New Delhi: Natco Pharma plans to launch around 8-10 new products in domestic branded formulations segment during the current year as it aims to grow over 20 per cent year-on-year during the period.


    The Hyderabad-based drug firm also plans to maintain its leadership position in oncology and gastro hepatology segment during the year as part of its short-term growth plan.


    Besides, the company is looking at gaining traction in the newly launched cardiology and diabetology (CnD) division, Natco Pharma said in an investor presentation.



    During the year, the company also plans to expand its Hepatitis-C product portfolio.

    Natco has already launched an oral fixed-dose combination of Sofosbuvir and Velapatasvir under its brand Velpanat.


    The medicine covers all genotypes ranging from 1 to 6. There is limited competition in the drug segment with only one other competitor in the domestic market, Natco said adding that it plans to launch the product in various international markets.


    Besides, it is looking at extension of the Tamiflu franchise via launch of a suspension version.


    The company said it is focussing at complex generics in the US market.


    It has a rich pipeline of niche and complex generics for the US market. The company has filed for 43 niche abbreviated new drug applications (ANDA) while the USFDA has already approved 22 of its applications.


    Beyond 2020, the company is looking at entering into "new attractive segments" in the branded formulations vertical.


    The drug firm, however, did not share details.


    For the year ended March 31, the company posted consolidated net profit of Rs 486 crore against Rs 157.1 crore last year, showing three-fold growth in profit.


    Total revenue for the year rose to Rs 2,078.9 crore from Rs 1,089.7 crore for 2015-16, reflecting an year-on-year growth of 90.8 per cent.


    Natco Pharma currently has seven manufacturing facilities spread across the country and employs more than 4,000 people.

    abbreviated new drug applicationscardiologydiabetologydomestic branded formulationsgastrohepatologyhepatitis CLaunchNatco pharmaoncologysofosbuvirTamifluUSFDAVelapatasvirVelpanat
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok